Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Liver Cancer Therapeutics Market Revenue Growth On Track For A 16.5% CAGR Through 2030
The liver cancer therapeutics market size has shown significant expansion in recent years. It will grow from $2.94 billion in 2025 to $3.44 billion in 2026 at a compound annual growth rate (CAGR) of 16.8%. The growth observed in previous periods is attributable to factors such as the increasing worldwide prevalence of liver cancer, the restricted efficacy of conventional chemotherapy, heightened awareness regarding early diagnosis, the expansion of specialized oncology treatment centers, and the regulatory approvals granted to targeted therapeutic options.
The liver cancer therapeutics market size is anticipated to undergo significant expansion in the upcoming years. It is projected to achieve a valuation of $6.34 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.5%. This expected growth during the forecast period stems from the development of immuno-oncology pipelines, the rising incidence of chronic liver diseases, innovations in biomarker-driven therapies, increased healthcare expenditure allocated to cancer care, and the broader implementation of personalized oncology treatment strategies. Notable trends within the forecast period encompass the increasing adoption of immunotherapy for liver cancer, the greater utilization of targeted therapies for advanced stages of the disease, a growing preference for combination treatment regimens, the expansion of precision medicine methodologies, and an increase in clinical trials for novel liver cancer drugs.
Get A Free Sample Report With In-Depth Market Insights:
Liver Cancer Therapeutics Market Growth Factors: What’s Supporting Expansion?
The anticipated rise in hepatitis B infections is set to stimulate the growth of the liver cancer therapeutics market. Hepatitis B is a viral disease caused by the hepatitis B virus (HBV) that primarily impacts the liver, potentially leading to both short-term (acute) and long-term (chronic) health complications, notably liver cancer. The increase in hepatitis B infections is partly influenced by the growing prevalence of injection drug use, which facilitates the virus’s spread through shared contaminated needles and syringes. Liver cancer therapeutics become crucial for hepatitis B infections because chronic infection can result in persistent liver inflammation and cellular damage, substantially elevating the risk of developing malignant liver conditions over time. Illustratively, in July 2025, the World Health Organization, a Switzerland-based health organization, stated that there are approximately 1.2 million new HBV infections globally every year. Therefore, the escalating incidence of hepatitis B infections is expected to propel the expansion of the liver cancer therapeutics market.
Liver Cancer Therapeutics Market Segment Analysis: What Are The Core Market Categories?
The liver cancer therapeutics market covered in this report is segmented –
1) By Type: Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Other Types
2) By Therapy Type: Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, Other Therapy Types
3) By Distribution Channel Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By End-Users: Pediatrics, Adults
Subsegments:
1) By Hepatocellular Carcinoma: Localized Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma
3) By Hepatoblastoma: Standard-Risk Hepatoblastoma, High-Risk Hepatoblastoma, Metastatic Hepatoblastoma
4) By Other Types: Fibrolamellar Carcinoma, Angiosarcoma Of The Liver, Hemangiosarcoma
Liver Cancer Therapeutics Market Industry Trends: What’s Reshaping Demand?
Leading companies in the liver cancer therapeutics market are concentrating on developing innovative treatments, such as prescription immunotherapy medications, to achieve long-lasting effects. These prescription immunotherapy drugs work by either enhancing or suppressing the body’s immune system to help combat specific conditions like cancer or chronic infections, through targeting and modulating immune responses. For instance, in April 2025, Bristol Myers Squibb, a US-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval of Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment for adult patients with hepatocellular carcinoma (HCC), the most common primary liver cancer, that is either incurable or has spread. This product’s unique aspect is that its approval is founded on the results from the global Phase 3 randomized, open-label CheckMate-9DW trial. In this study, patients with metastatic or incurable HCC who had not previously received systemic therapy were randomly assigned to receive Opdivo plus Yervoy in conjunction with the investigator’s choice of tyrosine kinase inhibitor monotherapy (either lenvatinib or sorafenib). The combination therapy demonstrated statistically significant improvements in overall survival (OS) and overall response rate (ORR) when compared to the control arm, distinguishing it as the only trial supporting an FDA approval that shows superior results in this setting.
Liver Cancer Therapeutics Market Top Companies Driving Competitive Growth
Major companies operating in the liver cancer therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca PLC, Amgen Inc., Eli Lilly and Company , Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Ipsen, Exelixis Inc., BeiGene Ltd., Hutchmed, Celgene Corporation, Zymeworks Inc., Can-Fite BioPharma, Onyx Pharmaceuticals Inc.
View The Full Liver Cancer Therapeutics Market Report:
Liver Cancer Therapeutics Market Top Region By Revenue And Market Share
North America was the largest region in the liver cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
